The arrival of Retatrutide ZPHC, at a dosage of 120mg, is creating considerable interest within the weight loss community. This novel dual GIP and GLP-1 agonist medication appears to deliver significant improvements in body loss compared to existing therapies. Preliminary patient trials have demonstrated significant reductions in weight , potential